Table 2.
Comparison of three PSA response groups (PR, SD, PD) for various characteristics by one-way ANOVA and Welch’s test
| Characteristic | Overall Mean ± SD |
PR Mean ± SD |
SD Mean ± SD |
PD Mean ± SD |
P value |
|---|---|---|---|---|---|
| Age (years) | 67.7 ± 8.91 | 70.2 ± 8.98 | 65.4 ± 9.39 | 72.3 ± 5.85 | 0.3301 |
| Haemoglobin (g/dl) | 10.4 ± 1.55 | 10.9 ± 1.56 | 10.4 ± 1.68 | 9.78 ± 1.18 | 0.6030 |
| Gleason score | 8.27 ± 0.77 | 8.00 ± 1.22 | 8.38 ± 0.51 | 8.25 ± 0.96 | 0.6560 |
| Time interval between first diagnosis of prostate cancer & referred for Lu177-PSMA therapy (months) | 48.7 ± 27.6 | 67.2 ± 41.0 | 43.6 ± 22.6 | 42.3 ± 17.3 | 0.5128* |
| Lu177-PSMA dose (GBq) | 6.88 ± 1.22 | 7.43 ± 0.27 | 7.19 ± 0.92 | 5.16 ± 1.48 | 0.0026 |
| ECOG (0–5) | 3.32 ± 0.57 | 3.00 ± 0.00 | 3.46 ± 0.52 | 3.25 ± 0.96 | 0.3069 |
| VAS (0–10) | 5.18 ± 2.15 | 4.60 ± 2.30 | 5.38 ± 2.40 | 5.25 ± 1.26 | 0.8010 |
| AQS (0–6) | 3.64 ± 0.49 | 3.80 ± 0.44 | 3.54 ± 0.52 | 3.75 ± 0.50 | 0.5504 |
PSA prostate-specific antigen, PR partial response, SD stable disease, PD progressive disease, ANOVA analysis of variance, Mean ± SD mean ± standard deviation, Lu177-PSMA lutetium 177 prostate-specific membrane antigen, GBq giga becquerel, EGOG Eastern Cooperative Oncology Group, VAS visual analogue scale, AQS Analgesic Quantification scale
*calculated by Welch’s test